Daily non-political popular news in brief.
Studies attribute recent increase in multiple myeloma survival to novel therapies
11-01-2007 · EurekAlert!Multiple myeloma is one of the most common and devastating bone marrow cancers in the US, but survival rates have risen dramatically over the past decade. Recent analyses suggest that this trend may be attributed to new types of drugs and aggressive therapeutic interventions such as stem cell transplantation, according to the results of two studies prepublished online in Blood, the official journal of the American Society of Hematology.
Read more »
Keywords: studies, attribute, multiple, myeloma, survival, novel, therapies, study, therapy
« Previous | Next »
Similar news on "Studies attribute recent increase in multiple myeloma survival to novel therapies":
- Diverse genetic abnormalities lead to NF-κB activation in multiple myeloma
08-13-2007 · EurekAlert!
Two new studies may lead to the development of more effective therapies for individuals with multiple myeloma, a common and incurable blood cell cancer. The research, published by Cell Press in the August issue of the journal Cancer Cell, provides new insight into the molecular mechanisms that underlie aberrant NF-κB activity in MM tumor cells and underscores the relevance of the signaling pathway as a target for MM therapy.
Similar news · Read more »
- Phase I study of novel gene therapy for HIV
11-06-2006 · EurekAlert!
The results are in for Phase I clinical trials of a gene therapy for AIDS. The trial was conducted at U-Penn where five patients with chronic HIV who had failed prior therapies were given a one-time infusion. They all tolerated the therapy and showed improved immune system response. This is the first publication of an effective gene therapy for AIDS to show positive clinical results in the peer review literature.
Similar news · Read more »
- Studies at cancer conference show new therapies changing outlook for blood cancer patients
12-08-2006 · EurekAlert!
The International Myeloma Foundation (IMF) -- conducting research and providing education, advocacy and support for myeloma patients, families, researchers and physicians -- today noted that multiple studies presented at the 2006 Annual Meeting of the American Society of Hematology (ASH) illustrate the breadth of the gains being made in the treatment of multiple myeloma and related blood cancers.
Similar news · Read more »
- Mayo Clinic Cancer Center researcher finds mold by-product kills multiple myeloma
04-15-2007 · EurekAlert!
Mayo Clinic Cancer Center researchers have found that chaetocin, a by-product of a common wood mold, has promise as a new anti-myeloma agent. Results of their study, being presented today at the American Association for Cancer Research annual meeting, show the by-product to be more effective than currently used therapies at killing multiple myeloma cells.
Similar news · Read more »
- Stroke victims may benefit from stem cell transplants
01-28-2008 · EurekAlert!
Two studies published in the current issue of Cell Transplantation examine the potential for cell transplants to benefit stroke victims. When injected into animal models and tracked via chemical tags and imaging, mensenchymal stem cells in one study, and bone marrow stromal cells in a second study, migrated within one to two weeks to affected brain areas and became therapeutically active. Both studies suggest that novel stem cell therapies can be developed.
Similar news · Read more »
- Nodal status is best predictor of outcome after neoadjuvant therapy for esophageal cancer
07-13-2007 · EurekAlert!
The number of lymph nodes that contain evidence of cancer is the best predictor of the effectiveness of adding chemotherapy and radiation to a treatment plan prior to surgery in individuals with esophageal cancer, according to a study published last month in the Annals of Surgery. The authors say their finding is particularly important because the focus of recent pathological studies of response to neoadjuvant therapies has been on the primary tumor rather than nodal sites.
Similar news · Read more »
- Mayo Clinic -- Collaborating to move treatment research forward
12-12-2006 · EurekAlert!
Novel therapies are greatly improving the long-term outlook for patients with multiple myeloma, say researchers at Mayo Clinic Cancer Center, who have led efforts in testing these treatments and moving them quickly into first-line therapies.
Similar news · Read more »
- Building stronger bones, 1 stem cell at a time
01-24-2008 · EurekAlert!
Mesenchymal stem cells are capable of giving rise to various cell types through a process known as differentiation. A new study has determined that the anti-tumor drug bortezomib targets MSCs and leads to bone cell-specific differentiation. These data led the authors to suggest that Bzb might be a novel therapy for bone loss in individuals with osteoporosis and those with cancers accompanied by severe bone disease, such as myeloma.
Similar news · Read more »
- Study shows interruption of antiretroviral therapy increases risk of disease and death
11-30-2006 · EurekAlert!
Findings from one of the largest HIV/AIDS therapy studies show that a specific strategy of interrupting antiretroviral therapy more than doubles the risk of AIDS or death from any cause. Researchers affiliated with the Mailman School of Public Health led a large multi-center international study, known as Strategies for Management of Anti-Retroviral Therapies, or SMART, comparing two treatment strategies for people with human immunodeficiency virus. Findings demonstrate the value of continuous antiretroviral therapy.
Similar news · Read more »
- Low-dose aspirin beats high-dose after cardiac surgery
03-24-2007 · EurekAlert!
The use of medicines to fight cardiovascular disease has been a primary focus of research in this area for the past several decades, as combinations of interventions and medicinal therapy have gradually begun to increase long-term survival rates. Two studies presented today at the American College of Cardiology’s 56th Annual Scientific Session look at the measurable impact of the use of aspirin and other maintenance therapies.
Similar news · Read more »
